undamentalytics Newsletter
Sign in

Phibro Animal Health Corp (PAHC) stock

Add to watchlist

Add holding +

NASDAQ: PAHC Nasdaq Pharmaceuticals Next results ~November 4, 2026

C+ Fundamentals grade

Phibro Animal Health Corp is a US-listed company in the pharmaceuticals industry. Its financial year ends in June.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: after-tax interest is 106% of the cash flow left for shareholders; our flat discount rate doesn't yet reflect debt this heavy.

Price vs value

Under review: after-tax interest is 106% of the cash flow left for shareholders; our flat discount rate doesn't yet reflect debt this heavy. We'll show the comparison once resolved.

Phibro Animal Health Corp valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 2 selling1 purchase and 109 sales by directors and officers, last 12 monthsInsider trades
  • Funds112 adding, 155 cuttingOf 46 active managers that changed their stake, 21 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Phibro Animal Health files

Where Phibro Animal Health stands after its latest 10-K

Revenue for the twelve months to June 2026 was $1.52bn, up 17.1% on a year earlier, slower than the 26.0% growth a quarter earlier. That growth ranks 3 of 18 among the pharmaceuticals companies we cover. Free-cash-flow margin fell to 0.6% from 3.2% a year earlier. Operating margin widened to 12.8% from 8.5%. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 2 of our 3 financial-health checks.

Our model value for Phibro Animal Health is under review, so past values are not shown until it is resolved.

Source: 10-K filed August 26, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Phibro Animal Health Corp's trailing-twelve-month revenue grew 17.1% year on year, with a free-cash-flow margin of 0.6%. Where it stands out: stock pay as % of revenue of 0.1% ranks 2 of 69 pharmaceuticals companies we cover.

Our discounted-cash-flow model values the business at ~$42 per share in the base case (~$27–$60 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 76.4% while net income grew 106.6%: a 183pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 17.1% over the last 12 months, against a median of 10.0% for pharmaceuticals companies we cover.
  • Margins widening. Operating margin is up 4.3 points on a year ago.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Results due soon. Results are expected around 4 November; the share price can move sharply on the day.
  • Growth slowing. The growth rate is 8.9 points lower than a quarter earlier.
  • Volatile shares. Over the past year the shares showed annualised volatility of 54% and a beta of 0.7 against the S&P 500.
  • Weak cash conversion. Free cash flow was 10% of net income over the last 12 months.
  • Below peers: gross margin. Gross margin of 33.8% ranks 47 of 59 pharmaceuticals companies we cover (median 59.8%).

Latest results: FY2026 Q4

Filed August 26, 2026
Earnings per share
$0.85 against an average estimate of $0.73: beat by 17.1%
Revenue
$397m, up 4.8% on a year earlier
Share reaction
+1.2% in the first session after the results on August 26, 2026, against +0.7% for the S&P 500
Next report
November 4, 2026; average EPS estimate $0.78

Phibro Animal Health's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-3.4%
  • 1 week-2.5%
  • 1 month+0.5%
  • This year+4.7%
  • 1 year-12.6%
  • 5 years+94.1%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$1.5B
Operating margin
12.8%
Net margin
6.6%
EPS (TTM, diluted)
$2.43

Growth

Revenue growth
+17.1%
Change in growth rate
−8.9 pts
Share count change
+0.7%

Cash

Free cash flow (TTM)
$9.9M
FCF margin
0.6%
Stock pay % of revenue
0.1%

Earnings

Last results
August 26, 2026
Next results (est.)
November 4, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Dividend
  3. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Phibro Animal Health Corp valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: held for review: after-tax interest is 106% of the cash flow left for shareholders; our flat discount rate doesn't yet reflect debt this heavy.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Phibro Animal Health Corp as an operating company, with every model that fits that kind of business. Cost of equity 9%: the 10-year Treasury yield (4.9%) plus a beta of 0.91 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$34 ~$35–$71 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$18 ~$14–$25 Included
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$20 ~$17–$24 Included
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Phibro Animal Health Corp with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20162017201820192020202120222023202420252026
Share price$15.13$30.46$38.25$26.76$22.58$25.37$17.18$12.74$16.17$25.14$31.30
Market value$604525$1m$2m$1m$915m$1.0bn$696m$516m$655m$1.0bn$1.3bn
+ Net debt (− = net cash)$251m$194m−$29m$174m$200m$256m$215m$294m$243m$570m$676m
Enterprise value$251m$195m−$28m$175m$1.1bn$1.3bn$910m$810m$898m$1.6bn$2.0bn
Multiples
Price / sales 0.0x0.0x0.0x0.0x1.1x1.2x0.7x0.5x0.6x0.8x0.8x
Price / earnings 0.0x0.0x0.0x0.0x27.3x18.9x14.2x15.8xn/m21.2x12.9x
Price / free cash flow 0.7x0.0x0.0x0.1x36.1x54.1x——14.1x24.5x130.0x
EV / EBITDA 2.3x1.6xn/m1.6x11.0x12.0x8.2x7.7x10.0x10.2x8.0x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

49 /100

Moderate moat

How hard Phibro Animal Health's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 7 / 20

    Cash operating profit has been a median 6.6% of total assets over 10 years.

  • Pricing power 12 / 20

    Gross margin has been a median 32.0%, moving by 1.1 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median 8.8%; its worst year was 5.2%.

  • Cash conversion 9 / 20

    Free cash flow was positive in 8 of 10 years, at a median 2.7% of revenue.

  • Discipline 16 / 20

    The diluted share count rose 1.1% over five years; stock-based pay has been a median 0.1% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (54 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, after the close. Analysts expect revenue of $383m and EPS of $0.78 (range $0.76 to $0.81) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $3.50 +9% $1.6bn +4%
Next $3.85 +10% $1.6bn +4%

Next year's EPS estimate has moved +4.4% in 90 days, across 3 analysts.

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.73 $0.85 +17.1%
Mar 2026 $0.71 $0.76 +6.5%
Dec 2025 $0.67 $0.87 +29.8%
Sept 2025 $0.60 $0.73 +21.1%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

3 analysts, Oct 2026
Buy133%
Hold267%
Sell00%

Monthly trend

  1. Oct 2026123
  2. Sep 20261214
  3. Aug 20261315
  4. Jul 20261315

Counts of recommendations published by analysts covering Phibro Animal Health Corp, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
7.0%
of tradable shares
Days to cover
4.06
at average volume
Short interest, 1 month
−16%
to September 30, 2026
Held by institutions
—
of shares
Held by insiders
0.9%
of shares
Employees
2,605
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −6.7%

$41.54 on October 31, 2025 to $38.74

ThenNowEffect
Revenue (last 12 months) $1.3bn $1.5bn +17.1%
Net margin 3.7% 6.6% +76.4%
P/E multiple 35.0x 15.9x −54.5%
Share count 41m 41m −0.7%

Biggest factor: p/e multiple.

Last 3 years +234.8%

$11.57 on November 3, 2023 to $38.74

ThenNowEffect
Revenue (last 12 months) $978m $1.5bn +55.2%
Net margin 3.3% 6.6% +97.0%
P/E multiple 14.4x 15.9x +10.7%
Share count 41m 41m −1.1%

Biggest factor: net margin.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
PAHC+7%−32%−10%+86%+81%+5%
Industry peers (median)−20%−52%−14%−2%+7%−14%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
PAHC75%42%50%75%67%64%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
PAHC−36%−44%−40%−18%−37%−52%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 3, 2015: 80% from August 27, 2018 to November 10, 2023. Getting back needed a 391% gain, reached on November 10, 2025, 731 days after the low.

Price behaviour

52-week range
$28.31 – $59.14
From 52-week high
−34.5%
vs 50-day average
+4.6%
vs 200-day average
−5.6%
Volatility (1 year)
54%
Beta vs S&P 500
0.70

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
10 up, 2 down
typical move ±10.8%
After a week
9 up, 3 down
typical move ±15.5%
After a month
8 up, 4 down
typical move ±13.5%
Results releasedNext dayS&P 500 next day5 days21 days
August 26, 2026 +1.2% +0.7% +11.5% −3.8%
May 6, 2026 −23.3% +1.1% −37.3% −42.1%
February 4, 2026 +21.0% −1.7% +24.7% +16.3%
November 5, 2025 +2.2% −0.7% +7.6% −6.8%
August 27, 2025 +17.8% +0.6% +20.1% +19.3%
May 7, 2025 +16.9% +1.1% +22.7% +27.1%
February 5, 2025 +11.6% +0.8% +11.7% +7.9%
November 6, 2024 +2.8% +3.3% +10.6% +2.1%
August 28, 2024 +1.9% −0.6% −7.2% +5.4%
May 8, 2024 +5.5% +0.6% +8.8% +3.0%
February 7, 2024 +5.9% +0.9% +10.4% +20.2%
November 8, 2023 −18.9% −0.7% −13.2% −7.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Phibro Animal Health Corp in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Phibro Animal Health Corp
$800M $1B $1.2B $1.4B $1.6B FY24 Q1 FY24 Q4 FY25 Q3 FY26 Q4 Revenue (TTM), FY24 Q1: $976.7M Revenue (TTM), FY24 Q2: $982M Revenue (TTM), FY24 Q3: $999.6M Revenue (TTM), FY24 Q4: $1B Revenue (TTM), FY25 Q1: $1B Revenue (TTM), FY25 Q2: $1.1B Revenue (TTM), FY25 Q3: $1.2B Revenue (TTM), FY25 Q4: $1.3B Revenue (TTM), FY26 Q1: $1.4B Revenue (TTM), FY26 Q2: $1.5B Revenue (TTM), FY26 Q3: $1.5B Revenue (TTM), FY26 Q4: $1.5B $1.5B

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue (TTM)
FY24 Q1 $976.7M
FY24 Q2 $982M
FY24 Q3 $999.6M
FY24 Q4 $1B
FY25 Q1 $1B
FY25 Q2 $1.1B
FY25 Q3 $1.2B
FY25 Q4 $1.3B
FY26 Q1 $1.4B
FY26 Q2 $1.5B
FY26 Q3 $1.5B
FY26 Q4 $1.5B
Revenue growth, TTM YoY Phibro Animal Health Corp
0% 10% 20% 30% 40% FY24 Q1 FY24 Q4 FY25 Q3 FY26 Q4 Revenue growth, TTM YoY, FY24 Q1: 1.7% Revenue growth, TTM YoY, FY24 Q2: 1.0% Revenue growth, TTM YoY, FY24 Q3: 2.2% Revenue growth, TTM YoY, FY24 Q4: 4.1% Revenue growth, TTM YoY, FY25 Q1: 7.2% Revenue growth, TTM YoY, FY25 Q2: 12.6% Revenue growth, TTM YoY, FY25 Q3: 19.1% Revenue growth, TTM YoY, FY25 Q4: 27.4% Revenue growth, TTM YoY, FY26 Q1: 33.7% Revenue growth, TTM YoY, FY26 Q2: 32.4% Revenue growth, TTM YoY, FY26 Q3: 26.0% Revenue growth, TTM YoY, FY26 Q4: 17.1% 17.1%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue growth, TTM YoY
FY24 Q1 1.7%
FY24 Q2 1.0%
FY24 Q3 2.2%
FY24 Q4 4.1%
FY25 Q1 7.2%
FY25 Q2 12.6%
FY25 Q3 19.1%
FY25 Q4 27.4%
FY26 Q1 33.7%
FY26 Q2 32.4%
FY26 Q3 26.0%
FY26 Q4 17.1%
Operating margin (TTM) Phibro Animal Health Corp
4% 6% 8% 10% 12% 14% FY24 Q1 FY24 Q4 FY25 Q3 FY26 Q4 Operating margin (TTM), FY24 Q1: 5.9% Operating margin (TTM), FY24 Q2: 5.8% Operating margin (TTM), FY24 Q3: 5.9% Operating margin (TTM), FY24 Q4: 5.2% Operating margin (TTM), FY25 Q1: 6.9% Operating margin (TTM), FY25 Q2: 7.4% Operating margin (TTM), FY25 Q3: 8.0% Operating margin (TTM), FY25 Q4: 8.5% Operating margin (TTM), FY26 Q1: 10.3% Operating margin (TTM), FY26 Q2: 11.5% Operating margin (TTM), FY26 Q3: 12.0% Operating margin (TTM), FY26 Q4: 12.8% 12.8%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Operating margin (TTM)
FY24 Q1 5.9%
FY24 Q2 5.8%
FY24 Q3 5.9%
FY24 Q4 5.2%
FY25 Q1 6.9%
FY25 Q2 7.4%
FY25 Q3 8.0%
FY25 Q4 8.5%
FY26 Q1 10.3%
FY26 Q2 11.5%
FY26 Q3 12.0%
FY26 Q4 12.8%
FCF margin (TTM) Phibro Animal Health Corp
0% 2% 4% 6% FY24 Q1 FY24 Q4 FY25 Q3 FY26 Q4 FCF margin (TTM), FY24 Q1: 0.4% FCF margin (TTM), FY24 Q2: 3.8% FCF margin (TTM), FY24 Q3: 4.0% FCF margin (TTM), FY24 Q4: 4.6% FCF margin (TTM), FY25 Q1: 3.9% FCF margin (TTM), FY25 Q2: 1.4% FCF margin (TTM), FY25 Q3: 4.1% FCF margin (TTM), FY25 Q4: 3.2% FCF margin (TTM), FY26 Q1: 2.4% FCF margin (TTM), FY26 Q2: 3.2% FCF margin (TTM), FY26 Q3: 0.9% FCF margin (TTM), FY26 Q4: 0.6% 0.6%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period FCF margin (TTM)
FY24 Q1 0.4%
FY24 Q2 3.8%
FY24 Q3 4.0%
FY24 Q4 4.6%
FY25 Q1 3.9%
FY25 Q2 1.4%
FY25 Q3 4.1%
FY25 Q4 3.2%
FY26 Q1 2.4%
FY26 Q2 3.2%
FY26 Q3 0.9%
FY26 Q4 0.6%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2012 Jun 2012 2013 Jun 2013 2014 Jun 2014 2015 Jun 2015 2016 Jun 2016 2017 Jun 2017 2018 Jun 2018 2019 Jun 2019 2020 Jun 2020 2021 Jun 2021 2022 Jun 2022 2023 Jun 2023 2024 Jun 2024 2025 Jun 2025 2026 Jun 2026
Income
Revenue 654 653 692 749 752 764 820 828 800 833 942 978 1,018 1,296 1,518
Gross profit 164 179 204 233 239 248 267 265 257 271 285 298 313 400 513
EBITDA 67 76 85 109 109 124 126 111 102 107 112 106 89 156 246
Operating income 49 57 64 88 86 98 99 83 69 75 79 72 53 110 194
Net income 7 25 −3 60 83 65 65 55 34 54 49 33 2 48 100
Diluted EPS $0.23 $0.82 −$0.10 $1.51 $2.07 $1.61 $1.61 $1.35 $0.83 $1.34 $1.21 $0.81 $0.06 $1.19 $2.43
Growth (year on year)
Revenue — −0.1% +5.9% +8.2% +0.4% +1.7% +7.3% +1.0% −3.3% +4.1% +13.1% +3.8% +4.1% +27.4% +17.1%
EBITDA — +13.3% +12.5% +28.2% −0.1% +13.5% +1.6% −12.0% −8.4% +5.1% +4.6% −5.2% −15.5% +74.4% +57.6%
Operating income — +15.0% +12.4% +37.4% −2.2% +14.2% +1.0% −15.9% −16.9% +8.2% +5.5% −9.0% −25.8% +107.2% +76.0%
Net income — — −112.6% — +37.2% −21.9% +0.4% −15.7% −38.7% +62.1% −9.6% −33.7% −92.6% — +106.6%
Diluted EPS — — −112.2% — +37.1% −22.2% 0.0% −16.1% −38.5% +61.4% −9.7% −33.1% −92.6% — +104.2%
Margins
Gross margin 25.1% 27.4% 29.5% 31.2% 31.8% 32.5% 32.5% 32.0% 32.1% 32.6% 30.3% 30.5% 30.8% 30.9% 33.8%
EBITDA margin 10.2% 11.6% 12.3% 14.6% 14.5% 16.2% 15.4% 13.4% 12.7% 12.8% 11.9% 10.8% 8.8% 12.0% 16.2%
Operating margin 7.5% 8.7% 9.2% 11.7% 11.4% 12.8% 12.1% 10.1% 8.6% 9.0% 8.4% 7.3% 5.2% 8.5% 12.8%
Net margin 1.1% 3.8% −0.5% 8.1% 11.0% 8.5% 7.9% 6.6% 4.2% 6.5% 5.2% 3.3% 0.2% 3.7% 6.6%
Free-cash-flow margin 2.6% −2.8% −3.0% 6.5% 0.1% 10.1% 6.3% 2.1% 3.2% 2.3% −0.6% −3.9% 4.6% 3.2% 0.6%
Cash flow
Cash from operations 32 1 −1 69 37 98 70 47 59 48 32 13 88 80 69
Capital spending 15 20 20 20 36 21 19 30 34 29 37 52 41 38 59
Free cash flow 17 −19 −21 49 1 78 51 17 25 19 −5 −38 46 42 10
Stock-based pay 0 0 0 — — 0 0 2 2 1 — — 0 1 2
Free cash flow after stock pay 17 −19 −21 — — 78 51 15 23 18 — — 46 41 8
Balance sheet
Cash 54 27 12 29 34 56 29 58 36 50 74 41 71 68 61
Total debt 0 298 290 287 284 250 — 231 237 306 289 335 313 638 738
Net debt (negative = net cash) −54 270 278 258 251 194 −29 174 200 256 215 294 243 570 676
Diluted shares — — 32m 40m — — — — 41m 41m 41m 41m 41m 41m 41m
Returned to shareholders
Dividends — 3 25 16 16 16 16 19 19 19 19 19 19 19 19
Total returned — 3 25 16 16 16 16 19 19 19 19 19 19 19 19

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 3 checks passed · June 30, 2026
What it owns · $1.5bn
Short-term assets $936mLonger-term assets $566m
What it owes, and who funded it · $1.5bn
Short-term liabilities $316mLonger-term liabilities $799mShareholders' equity $385m
  • Short-term assets cover short-term liabilities $936m of assets due within a year against $316m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $936m short-term assets against $799m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of $194m against $46m of interest.

From Phibro Animal Health Corp's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Dividends (TTM)
$19.5M
Returned to shareholders
197%
of free cash flow
Diluted share count
+0.7%
year over year
Total shareholder yield
1.2%
dividends 1.2% + buybacks 0.0% of market value
Dividend payout ratio
20%
of net income paid out
Sales & admin spending
21.0%
of revenue
Days sales outstanding
57 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in pharmaceuticals
Last 12 months unless stated PAHC LNTH INDV TRLV PBH ANIP Median
Revenue, last 12 months $1.5bn $1.6bn $1.4bn $1.1bn $1.1bn $978m $276m
Revenue growth, last 12 months 17.1% 2.3% 16.3% −3.9% −1.4% 30.9% 9.9%
Revenue growth, 3-year average 15.8% 11.4% — −0.6% −0.7% 34.6% 5.5%
Revenue growth, latest quarter 4.8% 2.7% 13.4% −10.3% 6.5% 25.9% 6.5%
Gross margin 33.8% 60.1% 85.0% 59.5% 53.5% 60.0% 62.0%
Operating margin 12.8% 19.4% 40.6% −24.3% 26.3% 15.4% −5.9%
Operating margin, 3-year average 8.9% 26.7% — −1.4% 28.6% 8.9% −7.4%
Net margin 6.6% 17.7% 32.8% −41.6% 15.6% 11.1% −7.3%
Cash from operations / revenue 4.5% 26.5% 7.0% 21.5% 22.6% 19.4% 10.2%
Free-cash-flow margin 0.6% 24.9% 2.3% 17.1% 21.3% 17.7% 8.6%
Free-cash-flow margin, 3-year average 2.8% 28.6% — 19.0% 22.4% 17.6% 7.4%
Stock pay / revenue 0.1% 5.0% 2.4% 1.8% 1.0% 4.2% 3.6%
Change in share count 0.7% −7.8% 0.0% 1.4% −3.6% 11.6% 1.9%

Median of all 75 companies we cover in pharmaceuticals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

75 pharmaceuticals companies
Measure Company Peer median Rank
Revenue growth Growth 17.1% 10.0% 26 of 74
Change in growth rate Growth -8.9pp -0.3pp 58 of 74
Gross margin Profitability 33.8% 59.8% 47 of 59
Operating margin Profitability 12.8% -5.9% 19 of 67
Net margin Profitability 6.6% -7.3% 25 of 75
Free-cash-flow margin Cash generation 0.6% 10.1% 48 of 74
Stock pay as % of revenue Cash generation 0.1% 3.6% 2 of 69
Long-term debt as % of assets Balance sheet 41.4% 23.8% 37 of 53
Change in share count Balance sheet 0.7% 1.5% 27 of 62
Days sales outstanding Balance sheet 57 days 72 days 16 of 59

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to June 30, 2026
Segments
Line of business Revenue Share YoY
Animal Health $1.2B 76.6% ▲ 20.7%
Mineral Nutrition $282M 18.6% ▲ 11.5%
Performance Products $73.5M 4.8% ▼ 8.3%
Products and services
Line of business Revenue Share YoY
Animal Health $1.2B 76.6% ▲ 20.7%
Medicated Feed Additives and Others $811M 69.8% ▲ 25.4%
Nutritional Specialties $195M 16.8% ▲ 8.8%
Vaccines $156M 13.5% ▲ 14.0%
Mineral Nutrition $282M 18.6% ▲ 11.5%
Performance Products $73.5M 4.8% ▼ 8.3%
Geography
Region Revenue Share YoY
United States $877M 57.8% ▲ 18.5%
Latin America and Canada $341M 22.4% ▲ 14.1%
EMEA $188M 12.4% ▲ 17.3%
Asia Pacific $112M 7.4% ▲ 15.3%

From Phibro Animal Health Corp's 10-K filed August 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$657M
Institutions reporting
206
Shares held vs prior quarter
▲ 3.3%
Positions opened / closed
33 / 80

Top buyers and sellers, Q2 2026: 112 institutions bought and 155 sold ; the biggest buyer was FMR LLC (+987K shares) and the biggest seller Acadian Asset Management LLC (−390K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $101M 3.2M 15.4% ▼ 1.1%
FMR LLC $99.2M 3.2M 15.1% ▲ 45.4%
State Street Corp $32.6M 1.0M 5.0% ▲ 9.3%
Millennium Management LLC $29.4M 937K 4.5% ▲ 1578.1%
Vanguard Capital Management LLC $29M 923K 4.4% ▲ 3.6%
Geode Capital Management, LLC $20.6M 657K 3.1% ▲ 8.7%
Lord, Abbett & Co. LLC $20.5M 653K 3.1% ▲ 64.3%
Dimensional Fund Advisors LP $16.7M 531K 2.5% ▲ 4.6%
Vanguard Portfolio Management LLC $16M 508K 2.4% ▲ 3.7%
Renaissance Technologies LLC $15.1M 481K 2.3% ▼ 16.7%
Castleknight Management LP $14.5M 461K 2.2% ▲ 507.8%
Morgan Stanley $13M 413K 2.0% ▲ 5.5%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Phibro Animal Health Corp's complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $317,700 1 trade by 1 insider, last 12 months Insider sales History → $28.1M 109 trades by 2 insiders · 100% under pre-set plans
Net ▼ $27.8M net selling
Insider Date Trade Shares Price Value
Corcoran E Thomas Director May 29, 2026 Buy 10,000 $31.77 $317,700
Bendheim Jack President and CEO May 7, 2026 Sell pre-set plan 1,350 $47.59 $64,247
Bendheim Jack President and CEO May 7, 2026 Sell pre-set plan 1,149 $48.31 $55,508
Bendheim Jack President and CEO May 7, 2026 Sell pre-set plan 2,029 $49.19 $99,807
Bendheim Jack President and CEO May 6, 2026 Sell pre-set plan 1,406 $58.13 $81,731
Bendheim Jack President and CEO May 6, 2026 Sell pre-set plan 5,634 $57.18 $322,152
Bendheim Jack President and CEO May 5, 2026 Sell pre-set plan 776 $56.37 $43,743
Bendheim Jack President and CEO May 5, 2026 Sell pre-set plan 6,264 $55.73 $349,093
Bendheim Jack President and CEO April 30, 2026 Sell pre-set plan 5,805 $52.65 $305,633
Bendheim Jack President and CEO April 30, 2026 Sell pre-set plan 1,235 $53.32 $65,850
Bendheim Jack President and CEO April 29, 2026 Sell pre-set plan 4,002 $52.70 $210,905
Bendheim Jack President and CEO April 29, 2026 Sell pre-set plan 3,038 $53.21 $161,652

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 4, 2026 estimated from the company's past filing pattern, not announced

  • August 26, 2026
  • May 6, 2026
  • February 4, 2026
  • November 5, 2025
  • August 27, 2025
  • May 7, 2025

Recent SEC filings

Data status

When each part of this page on Phibro Animal Health Corp was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Phibro Animal Health Corp in brief

What does Phibro Animal Health Corp do?
Phibro Animal Health Corp is a US-listed company in the pharmaceuticals industry. Its financial year ends in June.
What is Phibro Animal Health Corp's stock ticker?
Phibro Animal Health Corp trades under the ticker PAHC on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Phibro Animal Health Corp's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Phibro Animal Health Corp reported revenue of $1.5B, 17.1% higher than a year earlier, according to its SEC filings.
What is Phibro Animal Health Corp's free cash flow?
Phibro Animal Health Corp's free-cash-flow margin is 0.6% of revenue over the trailing twelve months, ranking 48 of the 74 pharmaceuticals companies we cover.
Who are Phibro Animal Health Corp's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., FMR LLC and State Street Corp. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Phibro Animal Health Corp's market cap?
On June 30, 2026, Phibro Animal Health Corp's market capitalisation was about $1.3B, with a price-to-earnings ratio of 12.9 and net debt of $676M. Market figures come from third-party market data and may be delayed.
Does Phibro Animal Health Corp pay a dividend?
Yes: Phibro Animal Health Corp paid $19.5M in dividends over the trailing twelve months, a dividend yield of 1.23% and a payout ratio of 19.5%.
Who are Phibro Animal Health Corp's competitors?
In our Pharmaceuticals peer group, the companies closest to Phibro Animal Health Corp are Lantheus Holdings, Inc., Indivior Pharmaceuticals, Inc., Trulieve Cannabis Corp., Prestige Consumer Healthcare Inc. and ANI Pharmaceuticals Inc. The side-by-side comparison below sets their revenue, margins and growth against Phibro Animal Health Corp's.
Are insiders buying or selling Phibro Animal Health Corp stock?
Over the last 12 months, Phibro Animal Health Corp's directors and officers reported 1 open-market purchases and 109 sales on Form 4. The insider trading page charts every trade.
When is Phibro Animal Health Corp's next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Phibro Animal Health Corp announces its own schedule.